Published in
The Primary Care Companion For CNS Disorders, 2(15)
DOI: 10.4088/pcc.12r01412
Links
- ORCID
- Physicians Postgraduate Press
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
Tools
A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer’s Disease
Journal article published in 2013 by
Agneta Nordberg 
,
Clive Ballard,
Roger Bullock,
Taher Darreh-Shori,
Monique Somogyi
,
Clive Ballard,
Roger Bullock,
Taher Darreh-Shori,
Monique Somogyi
This paper is available in a repository.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and neurologic conditions, such as Alzheimer’s disease (AD). The rationale for inhibiting cholinesterases in the management of AD, including clinical evidence supporting use of the dual acetylcholinesterase (AChE) and BuChE inhibitor rivastigmine, is discussed.